MYOS Signs Exclusive Supply Contract, Plans New Product R&D, With DIL

MYOS Signs Exclusive Supply Contract, Plans New Product R&D, With DIL 
CEDAR KNOLLS, NJ -- (Marketwired) -- 07/11/13 --  MYOS Corporation
(OTCBB: MYOS), a company focused on the discovery, development and
commercialization of products that improve human muscle health and
performance, today announced that it has signed an exclusive two-year
supply contract with the prestigious Deutsches Institut fur
Lebensmitteltechnik e.V. ("DIL") -- the German Institute for Food
Under the terms of the Contract, DIL will manufacture and supply the
Company with the breakthrough formula for its flagship MYO-X product
-- the first clinically proven natural myostatin inhibitor. MYOS will
benefit from a stable supply of product, manufactured to the highest
industry standards by a world class food technology leader, as well
as from long-term volume pricing and capitalizing on DIL's global
economies of scale.  
Further, this strategic alliance strengthens the Company's
competitive position, and serves as an important barrier to entry in
this emerging field of nutritional technology. Under this exclusive
supply relationship, MYOS has secured world class manufacturing for
its lead product and established the basis for future DIL research
and development on current and new products. 
"Execution of this supply contract goes well beyond a traditional
manufacturing relationship," said MYOS President and Chief Operating
Officer, Peter Levy. "DIL is our strategic partner, as DIL's
knowledge provides an important complement to our internal research
and development efforts. We are committed to creating a range of new
products with DIL and optimizing the methods of manufacturing to
ensure the highest product quality while reducing the cost of goods.  
MYOS' lead product, MYO-T12, currently sold as MYO-X at leading
nutritional retailers, is produced using the revolutionary technology
of High Pressure Pasteurization (HPP) which preserves the high
quality freshness of the natural ingredients. The use of HPP in MYOS'
manufacturing is an example of the technical contributions realized
in its relationship with DIL and helps ensure the highest product
"This contract is all the more significant given the excellent
traction we are seeing in the marketplace for
 MYO-X," Mr. Levy added.
"We anticipate this growth will accelerate as the public becomes
increasingly aware of muscle health and performance." 
DIL's current membership is comprised of only 140 distinguished
companies including global industry leaders such as H.J. Heinz, Mars,
Nestle, Pepsi, General Mills, Con Agra, and Simplot. DIL is one of
the world's finest research facilities developing and implementing
new food and nutritional technologies. DIL's stated mission is to
develop, "Knowledge for Superior Foods." To learn more about DIL,
About MYOS Corporation
 MYOS is a developmental stage company focused
on the discovery, development and commercialization of products that
improve human muscle health and performance. MYOS is the owner of
MYO-T12, the first clinically proven natural myostatin inhibitor.
Myostatin is a natural regulatory protein, which inhibits muscle
growth and recovery. Medical literature suggests that lowering
myostatin levels has many potential health benefits including
increased muscle mass, healthy weight management, improved energy
levels, stimulation of muscle healing as well as treating sarcopenia,
a condition of age-related loss of muscle mass. For more information
on MYO-T12 and to discover why MYOS is known as "The Muscle
Company,"(TM) visit 
The Company's first commercial product MYO-X, powered by MYO-T12, is
distributed by Maximum Human Performance (MHP) and is currently
available on popular e-tailer websites including, and in specialty retailers including GNC and
Vitamin Shoppe and others. MYOS believes that MYO-X, as well as
future products it envisions, will redefine existing standards for
muscle health.  
Forward-Looking Statements
 Any statements in this release that are
not historical facts are forward-looking statements. Actual results
may differ materially from those projected or implied in any
forward-looking statements. Such statements involve risks and
uncertainties, including but not limited to those relating to the
successful continued research of MYO-T12 and its effects on myostatin
inhibition, including research and development activities with DIL,
product and customer demand, the continued growth of repeat
purchases, market acceptance of our products, the ability to create
new products through research and development, the continued growth
in revenue, the ability to generate the forecasted revenue stream and
cash flow from sales of MYO-X, the ability to achieve a sustainable
profitable business, the effect of economic conditions, the ability
to protect our intellectual property rights, the continued growth and
expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail
stores, the ability to strengthen our manufacturing relationships and
reduce the costs of our products, competition from other providers
and products, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in our Securities and Exchange Commission filings.
We undertake no obligation to update or revise any forward-looking
statement for events or circumstances after the date on which such
statement is made except as required by law. 
These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure
or prevent any disease. 
Lindsey Penrose
MYOS VP - Business Development
T: (973) 509-0444
Press spacebar to pause and continue. Press esc to stop.